[link removed]
This past month of research advances include the finding that “silencing” certain populations of neurons ([link removed]) may stop seizures and the uncovering of a possible cause of memory impairments ([link removed]) in individuals with epilepsy. In addition, a study found that one in every four children ([link removed]) in the US with epilepsy has anxiety and/or depression, emphasizing the importance of investing resources into epilepsy and mental health.
Other exciting news for the epilepsy community includes the approval of a new nasally administered rescue medication called VALTOCO ([link removed]) and the expanded availability of the no-cost epilepsy gene panel testing program Behind the Seizure ([link removed]) ^® to a wider age range of children who have had an unprovoked seizure.
Summaries of these research discoveries and news highlights are below.
** Research Discoveries & News
------------------------------------------------------------
* Seizure Control: Seizures can be “switched off” in an animal model of epilepsy by silencing one particular set of neurons located in the brainstem, specifically in an area called the substantia nigra, according to research from the Georgetown University Medical Center. Zeroing in on specific neurons suggests that treatment for epilepsy can be improved, researchers say. Learn More ([link removed])
* Epilepsy and Memory: A new Cedars-Sinai study reveals how memory and abnormal brain activity are linked in patients with epilepsy. The data show that abnormal electrical pulses from specific brain cells are associated with a temporary kind of memory disruption called transient cognitive impairment. Learn More ([link removed])
* Epilepsy and Depression: A study utilizing data from the 2009-2010 National Survey of Children with Special Health Care Needs found that one in four US children with epilepsy has depression and/or anxiety. The study authors concluded that physicians should consider the various factors that are related to depression and anxiety in children with epilepsy so that at-risk children can be screened and managed appropriately. Learn More ([link removed])
* Treatment Approval: Neurelis, Inc. announced that the FDA has approved VALTOCO^® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in people with epilepsy 6 years of age and older. Learn More ([link removed])
* Genetic Testing: The no-cost epilepsy gene panel testing program Behind the Seizure^®, which aims to provide faster diagnosis for young children with epilepsy, is being extended to any child under the age of eight who has an unprovoked seizure. Learn More ([link removed])
------------------------------------------------------------
The CURE Epilepsy Research Mobile App ([link removed]) delivers research news to the palm of your hand! With frequent updates, you'll always be in-the-know about the latest in epilepsy science. Download today. iOS ([link removed]) | Android ([link removed])
------------------------------------------------------------
Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research. CURE is a non-profit 501(c)(3) tax-exempt organization. Our tax identification number is 36-4253176.
[link removed]
[link removed] [link removed] [link removed] [link removed] [link removed]
View this email in your browser. ([link removed])
Our mailing address is:
Citizens United for Research in Epilepsy (CURE)
420 Wabash Ave, Ste 650
Chicago, IL 60611
USA
Update your preferences ([link removed]) or unsubscribe from this list ([link removed])
In the past you provided Citizens United for Research in Epilepsy your email address. Occasionally, you will receive updates from CURE about epilepsy research and news.
